ATLANTA--(BUSINESS WIRE)--June 3, 2006--Amgen (NASDAQ:AMGN - News), the world's largest biotechnology company, today announced interim Phase 3 data suggesting Aranesp® (darbepoetin alfa) administered every three weeks with intravenous (IV) iron has the potential to further enhance the effectiveness of increasing patient hemoglobin levels to the recommended target of greater than or equal to 11 g/dL and reducing the need for red blood cell transfusions in cancer patients with chemotherapy-induced anemia. The data were presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta. (Abstract #8612)
